# Anti-Schistosomiasis Sm14-vaccine in Senegal

> **NCT05658614** · PHASE2 · UNKNOWN · sponsor: **Oswaldo Cruz Foundation** · enrollment: 120 (estimated)

## Conditions studied

- Schistosomiasis Mansoni
- Schistosomiasis Haematobium
- Vaccination; Infection

## Interventions

- **BIOLOGICAL:** Sm14 recombinant vaccine+ GLA-SE adjuvant

## Key facts

- **NCT ID:** NCT05658614
- **Lead sponsor:** Oswaldo Cruz Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2023-09-15
- **Final completion:** 2023-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05658614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05658614, "Anti-Schistosomiasis Sm14-vaccine in Senegal". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05658614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*